Serum drug concentrations to optimize switching from adalimumab to etanercept in rheumatoid arthritis
| Autor: | Gertjan Wolbink, R. F. van Vollenhoven, J. Ruwaard, Michael T. Nurmohamed, M. J. L `Ami, Theo Rispens, C. Krieckaert |
|---|---|
| Přispěvatelé: | Clinical Immunology and Rheumatology, AII - Inflammatory diseases, AMS - Ageing & Morbidty, Landsteiner Laboratory, Rheumatology, ACS - Atherosclerosis & ischemic syndromes |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Drug
Adult Male musculoskeletal diseases medicine.medical_specialty Necrosis media_common.quotation_subject Immunology Gastroenterology Etanercept Arthritis Rheumatoid 03 medical and health sciences 0302 clinical medicine Rheumatology Internal medicine medicine Adalimumab Immunology and Allergy Humans 030212 general & internal medicine Registries skin and connective tissue diseases media_common Netherlands 030203 arthritis & rheumatology business.industry Drug Substitution Tumor Necrosis Factor-alpha Patient Selection food and beverages General Medicine Serum concentration Middle Aged medicine.disease Blockade Treatment Outcome Rheumatoid arthritis Antirheumatic Agents Tumor necrosis factor alpha Female medicine.symptom Drug Monitoring business medicine.drug |
| Zdroj: | l’ Ami, M J, Ruwaard, J, Krieckaert, C L M, Nurmohamed, M T, van Vollenhoven, R F, Rispens, T & Wolbink, G J 2019, ' Serum drug concentrations to optimize switching from adalimumab to etanercept in rheumatoid arthritis ', Scandinavian Journal of Rheumatology, vol. 48, no. 4, pp. 266-270 . https://doi.org/10.1080/03009742.2019.1577915 Scandinavian journal of rheumatology, 48(4), 266-270. Informa Healthcare Scandinavian Journal of Rheumatology, 48(4), 266-270. Informa Healthcare |
| ISSN: | 0300-9742 |
| DOI: | 10.1080/03009742.2019.1577915 |
| Popis: | Objectives: Inadequate response to adalimumab can be caused by insufficient blockade of the target tumour necrosis factor (TNF) at low serum concentrations. In such cases, patients may respond to another TNF inhibitor. We investigated whether the serum adalimumab concentration is related to the efficacy of a second TNF inhibitor, etanercept, in rheumatoid arthritis (RA). Methods: Patients with RA starting etanercept treatment were prospectively observed in the Reade Rheumatology Registry. In patients previously on adalimumab, serum concentrations were determined before treatment discontinuation. According to this concentration, three subgroups were formed |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|